The Clinical Research Of The Treatment Of Chronic Gastritis Combined With Depression By Shugan Jieyu Capsule Combined With Western Medicine

Objective:Shugan Jieyu capsule is effective in the treatment ofdepression. This research adopts the randomized controlled trials toconduct clinical trial, aims to examine the clinical effect and safety ofShugan Jieyu capsule in the treatment of chronic gastritis combinedwith depression, and to provide a more efficient and safer clinicaltreatment scheme for those special patients.Method:We picked the patients who went to digestive medicaldepartment of Hubei Provincial Hospital of TCM for treatment from Julyof2012to January of2013. This accords to the treating standard ofwestern CG and the treating standard of CCMD-3depression.Traditional Chinese doctors argue that60cases of patients who haveLiver-stomach disharmony and suffer from liver depression and spleendeficiency. We arranged them into3groups of blank control group,treatment group and medicine control group, each group containing20patients. blank control group: only western medicine are provided fortreatment: Rabeprazole Sodium Enteric-coated Tablets(also called YuTianqing)10mg, Oral administration only, once a day,6weeks;Hydrotalcite Tablets(also called Wei Dimei)1g, oral administration, three times a day,2weeks; those patients suffer from Abdominaldistention or bile reflux gastritis we also give: mosapride citratedispersible tablets(also called Xin Luona)5mg, oral administration,three times a day; treatment group: Shugan Jieyu capsule is used onthe basis of the blank control group,2pieces, oral administration, twotimes a day,6weeks; medicine control group: Fluoxetine (Bai YouJie)are used on the basis of the blank control group,20mg, oraladministration, once a day,6weeks. We observed the clinical symptom,physical sign, HAMD scale, TESS scale and evaluated the clinical effect,anti-depression effect and safety of the medicine.Results:1.TCM syndromes：2people were cured,5people significant effect,10people also effect,overall response rate was85%of blank control group.5people were cured,10people significant effect,4people alsoeffect,overall response rate was95%of treatment group.,3peoplewere cured,8people significant effect,7people also effect,overallresponse rate was90%of drug control group. Comparison of treatmentgroup and blank control group clinical efficacy, P＜0.05, clinical effectsof the treatment group than the control group. Completely cure rate andtotal efficiency quite of the two groups, P＞0.05. For the treatmentgroup and the drug group the integrated clinical efficacy,the cure rate,and the total efficiency is equal, P＞0.05.2. Shaped signs mitigation mitigation and gastrospe: the treatmentgroup and the control group, epigastric fullness, belching, sleepdisorders, fatigue, flu symptoms difference was statistically significant,P＜0.05, treatment group better; two groups stomachease the pain,pantothenic acid, dry mouth, bitter taste in the mouth, bad breath, stoolcomparative efficacy (P＞0.05). Groups belching, dry mouth symptoms was statistically significant treatment group compared withthe drug control group, P＜0.05, treatment group better, othersymptoms were comparable (P＞0.05).3.Depression efficacy: before and after the treatment, the three groupscan effectively improve depression in patients with the situation beforeand after the HAMD score was statistically significant (P＜0.05). Butthe treatment group and the control group, the to improve depressionmore significant HAMD scores between the two groups after treatment(P＜0.01). Drug control group, the treatment group compared with theimprovement of depression in efficacy(P＞0.05).4. Untoward effect: adverse reactions in one week after taking the drugcontrol group, appeared excited to lead to sleep disorders or sleepdisorders aggravated by two cases, asked the patients to medicationtime after the adverse reactions disappeared. But after taking the firstsix weeks, one cases of dry mouth adverse reactions, which may beassociated with Fluoxetine adverse drug reactions. No adverse eventsrecorded in the treatment group and the control group.Conclusion1.The curative effect of Shugan Jieyu capsule combined with routinewestern medicine to treat chronic gastritispatients with depression ismore significant than just giving acid suppression, protect gastricmucosa, etc of conventional western medicine treatment.2.Conventional therapy and conventional therapy combined withantidepressant treatment both can improve the HAMD score ofchronic gastritis patients with depression,but the latter has moreremarkable effect.3.Shugan Jieyu capsules and the Fluoxetine has the sameantidepressant effect. 4.Shugan Jieyu capsule combination group is more effective to alleviatethe patients’ belch symptom than the Fluoxetine combination group.5.The Shugan Jieyu Capsule is more safe and effective than Fluoxetine,its worth further clinicalpromotion.